CAR-T in the body: A cautious step for myeloma patients

For patients with relapsed or refractory multiple myeloma, the promise of CAR-T therapy often collides with harsh realities: grueling apheresis procedures, manufacturing delays, and the risk of life-threatening side effects. A phase 1 study published in Nature Medicine this week offers a glimmer of a different path—one where the therapy is generated inside the patient’s body.

The trial, led by researchers at Memorial Sloan Kettering Cancer Center, tested an in vivo approach: a single infusion of lentiviral vectors designed to reprogram a patient’s own T cells to target BCMA, a protein abundant on myeloma cells. All five participants—each with advanced disease that had resisted multiple prior therapies—tolerated the treatment without dose-limiting toxicities, a critical hurdle for early-stage research.

Yet the study’s design reveals as much about its limits as its potential. With no control group and a sample size of five, the primary goal was safety, not efficacy. "Feasibility is not the same as proof," notes Dr. Carl June, a CAR-T pioneer not involved in the work. The absence of severe side effects is encouraging, but it’s a single data point in a field where immune overreactions like cytokine release syndrome remain a persistent risk.

The lentiviral delivery method itself carries unresolved questions. While the study confirmed the vectors could successfully insert the CAR construct into T cells, the durability of these in vivo-generated cells—and whether they can match the persistence of ex vivo-manufactured CAR-T—is unknown. Prior attempts at in vivo CAR-T have struggled with inconsistent engraftment, a challenge the authors acknowledge but do not fully resolve here.

For patients today, this changes nothing. The therapy remains firmly in the research stage, with no regulatory pathway yet defined. Even if scaled, it would likely face the same barriers as existing CAR-T: high costs, specialized infrastructure, and the need for careful patient selection. The FDA’s recent crackdown on unproven cell therapies underscores how far experimental approaches must travel to reach the clinic.

Still, the study’s careful execution stands out in a field often marked by hype. By focusing on safety first and transparently outlining the gaps—how many cells were actually reprogrammed? How long did they last?—the researchers provide a template for how early-stage trials should communicate progress without overpromising. "This is a tool, not a triumph," one oncologist remarked off-record. The distinction matters.

In other words, this is evidence of a possible method, not a validated therapy. The absence of toxicities in five patients is a necessary step, but it tells us nothing about whether the approach will shrink tumors, extend survival, or outperform existing treatments. Feasibility is the floor, not the ceiling.